Accès ouvert
2025
article
OpenAlex
Wenjing Luo, Jia Wen Xu, Chenggong Li, Lu Tang et autres
CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved high response rates in patients with B-cell lymphoma. However, treatment failure and relapse can be attributable to CAR-T cell dysfunction and the immunosuppression of the tumor microenvironment. Combination therapy emerges as a solution …
hk, cn
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Lu Tang, Huan Zhang, Fen Zhou, Qiuzhe Wei et autres
BACKGROUND: Chimeric antigen receptor T (CAR-T) therapy has substantially revolutionized the clinical outcomes of patients with hematologic malignancies, but the cancer-intrinsic mechanisms underlying resistance to CAR-T cells remain yet to be fully understood. This study aims to explore the molecular determinants of …
hk, cn, Malawi
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Chenggong Li, Jia Li Xu, Wenjing Luo, Danying Liao et autres
Multiple myeloma (MM) bears heterogeneous cells that poses a challenge for single-target immunotherapies. Here we constructed bispecific CS1-BCMA CAR-T cells aiming to augment BCMA targeting with CS1. Sixteen patients with relapsed or refractory (RR) MM received CS1-BCMA CAR-T infusion. Six patients (38%) …
hk, cn
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Wenjing Luo, Chenggong Li, Yinqiang Zhang, Xindi Wang et autres
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Anti-CD19 chimeric antigen receptor (CAR) T-cell treatment has showed about 60-80% of response rate in relapsed or refractory (R/R) B-cell lymphoma. However, approximately 40% of patients (PTs) achieved long-term remissions and …
hk, cn
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang et autres
Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum retention …
hk, cn
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang et autres
Abstract Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum …
hk, cn
(code pays fourni par la source)
2022
article
OpenAlex
Heng Mei, Lu Tang, Huan Zhang, Fen Zhou et autres
Chimeric antigen receptor T (CAR T) therapy has revolutionized clinic outcomes of patients with hematologic malignancies, but therapeutic failure due to cancer resistance and relapse remains one of the major obstacles faced by CAR T cell therapy. We herein performed an unbiased …
hk, cn
(code pays fourni par la source)
2022
article
OpenAlex
Chenggong Li, Xindi Wang, Zhuolin Wu, Wenjing Luo et autres
Background Bispecific CAR-T cell therapy has been proposed to mitigate some limitations of single-targeted CAR-T cells. CS1 plays a vital role in myeloma pathogenesis, and is also highly expressed on tumor cells in almost all patients (pts) with multiple myeloma (MM). Therefore, …
hk, cn
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Yinqiang Zhang, Fen Zhou, Zhuolin Wu, Yingnan Li et autres
Chimeric antigen receptor T (CAR-T) cells targeting CD19 have achieved great clinical responses in patients with relapsed or refractory (R/R) acute B lymphoblastic leukemia. However, severe adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome restrict it …
hk, cn
(code pays fourni par la source)